ࡱ> Root EntryRoot EntrypǤ*FileHeadermDocInfoYBodyText : HwpSummaryInformation.QPrvImage - PrvTextDocOptions `Ǥ`ǤScripts `ǤpǤJScriptVersion t DefaultJScriptq_LinkDocu  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPRSTUVWXZ[\]^_`abcdefghijklnoprsvwxyz{|}8] <\><Towards next-generation T cell therapy for Cancer> <\Դ><Due to its ability to recognize antigens in an MHC-independent manner, T cells that are engineered to express chimeric antigen receptor (CAR) can be a viable option for the tumors with low mutational burden. Indeed, the second-generation CD19-targeting CAR-T cells with an engineered signaling domain demonstrated unprecedented anti-leukemic responses in patients with refractory B-cell cancer, and became the first approved gene therapy for cancer last year. In light of their clinical success, there has been an explosion of interest in CAR-T cells for cancer immunotherapy. However, the inability to control the activity of this potent live drug has resulted in severe treatment related toxicities and the constraint in targeting more than one antigen have limited its general application. Furthermore, various immune-suppressive mechanisms present in the tumor microenvironment often severely limits the anti-tumor activity of CAR-T cells agains>GIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~ylv emâ+nF]/̭%~fw.`׶MLe|{03a/~xǍ+rѯ\f1G*'TߕI/~9?5ڽ6t XFo96]ڕvV\ta(!wQX]"X\F$܃q'cDι[A}fy,F&nZs y܎!]?f7 >9 wҍ 1bڊ&jzn֨Ph9#DuVFNܔaPZIܑjIy_mP(hhAvh%wfjc19)ߚx7n:ݩcssZjvhwmJ~B遢bgR򦩥[ H^*g)Y,w^kfi 6kx)yz:*,baeTN(ujvBH]v iު.2LqZ}'1gx@vhpꪡZCjaFxĩZm<eE)2Z" o,5G2.p|[js[5܄2GݰI\.՝V=wbOM{}BJi-xӆBˊ9¾&y+r*YhWo^+>'۷ǽn$cόf_:ιϾ l9Mc:_jCZ冴ݮ;'\6廞CYr?a @SV>wMnM w߼5ppF(54k@IoSY\ Xz̚ac,mqߋ>ͼ(σA%!ˋ!Z>ӥ"u027p< D, oLQj"힓q!43N9Jo=:@ԕ#t>Nb-;^ pJG&,#eEQk7ܢ}Cg/ʶ!7$Х`6O{pӣLYrw|& JQц괸H`q2ʜui~J +NQN1YMrfњ۠6Ud"n e.rz (4kz¤(,Ķ tTBEG6fJm9QiFQ5^KEԃ$,)H9CxQ1DsKBɦF*u+U;]HFjM! ӥleNTHg#æQ*~ 6N]/1ͣ+B.=MT'嫽XPh%T"v0;]k"ŃѴD,O4zf{&5rGiMZQy48%O'lzC7?-qj2/5[J&Vtk)tMy#ʟ׾oO cBZmu!;Ld/4%RӶm\M 3m`*[Fs* -e׃&nEfK#IO=u` =X K vXE,>6k=m5a,#K򘵇]m)fy%(u;Gvsg mmTXƎGkUidW;_n-Q#=+0NNz.[|E]c6և6$zDg$zÒ. I]w͗t"bw9kYfRSkAv]AAc#1?\DE c` ^b,+  1$\.!X\c@|;bvFZ >̛萳+Bӡ.񐴳Ʌѐʘ<Rj , Q@Z߉kƋmN=^{_#\a tHnh Q_&w:hergo ΪzEvDk qR=蔔E7)`ᨹ#uZSGxw~nBF r=6c}8:8]Zo.e^'}al_aCFyŰ ƈxqf0 w-վ݈͸Dٔi#2eD FSD߻?eyO<HWP Document Fileu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈xicities and the constraint in targeting more than one antigen have limited its general application. Furthermore, various immune-suppressive mechanisms present in the tumor microenvironment often severely limits the anti-tumor activity of CAR-T cells agains>WOhUf2Id["jpsaSm6ziL6QrTfffDR^D x@H/=OœPjyo7Cwx}{޷9:8?ޞB-SeZ wt;1YW{=6*-ܤ<"' %WФ$`)Y*uoZt`iلZi/wڐ 4;顪bxҼmdϋS>ߣ̩b3;Ssboym>_Z-9͋>U׋}nm;}VKkQ>3yӦ*V)Eh*}a.mZP+Z1mM2A.݊E p"},]k]tߕRyfB&g3gnNw9gď"mh%m<;}:0Iu[_s>%KT>+M(ю#-،qF5 4f+H*}qϸ˶71#4'glpžpJxR&$HVdp p>J'2mC}.^.?r-g\?as2q.WZw/wL 5`6.!$ dM0 nfbBP~9Hgp@`XK,Keɲ-KBGd=04.11$bݕ! "XPܻ%88$1MQfMþLi*R35X9z <`)|M[hW|a4V5q)8sGgpWs $g1"{cH=XIG΁ݻ SF{ 3ߢ} ubV<'UkdSҮ|{9byUVVL=ko œ}kIMYL⛶h˵76#tgјޱSɺN 8LC\q9}vA TkOkXv`Ĕ 1M~i\{f\%bQ0gY =i钱eɹcevZDsDs 4kŤԷ_ZxPZ* 0lTRCZ3.O.dc`YWOrObwXHcT5jf7,>uwͩyrb%